Biochemical markers of @entity75 , e.g. @entity385 , should reflect the volume of irreversibly damaged brain parenchyma and the clinical outcome in a single @entity1 in order to allow estimation of prognosis at an early stage. Tau protein, which derives predominantly from neurons and axons, is elevated in the cerebrospinal fluid of @entity1 with @entity179 . This makes tau protein a potential marker of @entity528 . In order to test this hypothesis, the current study aimed at showing that tau protein is measurable in the blood after acute @entity385 and that it correlates with clinical disability and @entity64 volume. In a longitudinal prospective study we measured tau protein serum levels with an ELISA in 30 @entity1 longitudinally after @entity385 . Tau protein was detectable within 5 days after @entity63 in the sera of 7/20 @entity1 with MRI-proven @entity1188 and in 2/10 @entity1 with transitory @entity63 attack; both of them had a small @entity1188 visible on the MRI scan. Tau protein was measurable within 6 h after symptom onset, peaked after 3-5 days and correlated with @entity1188 volume and disability after 3 months. In conclusion, serum tau protein is a candidate marker of @entity21 . In @entity64 , its clinical use is limited, because it is detectable only in a proportion of @entity1 .

Serum tau protein level as a marker of XXXX in acute @entity385 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia', 'ischemic'] @entity75 :: ('MESH:D001927', 'Disease') :: ['brain damage'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct', 'infarction'] @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative disease'] @entity21 :: ('MESH:D001480', 'Disease') :: ['axonal injury'] @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal/axonal injury'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity21 :: (MESH:D001480,Disease) :: ['axonal damage']
